WASHINGTON / RankWire.AI / – A groundbreaking study published in the journal Science reveals a rare inherited genetic mutation that can amplify an individual’s likelihood of developing lung cancer by approximately 25 times overall and as much as 60 times among non-smokers. The research, conducted by scientists at the Dana-Farber Cancer Institute in collaboration with the 23andMe Research Institute, analyzed anonymized genetic information from over 3.3 million people. The investigators identified the germline variation known as EGFR T790M as one of the most potent inherited risk factors for lung cancer ever documented.
This mutation affects the epidermal growth factor receptor gene, which controls cell growth and division in lung tissue. While somatic EGFR mutations acquired during a person’s lifetime are established drivers of non-small cell lung cancer, the T790M germline variation is inherited at birth and present in every cell. Data from the National Cancer Institute indicates that the mutation occurs in roughly 1 out of every 15,850 individuals in the United States. Lead author Dr. Jaclyn LoPiccolo stated that carriers of the variant face about a 62-fold increased risk of lung cancer among never-smokers, compared to approximately an 11-fold increase in those with a history of smoking.
Genealogical research has shown that the EGFR T790M variant is disproportionately concentrated in populations across Tennessee and Alabama within the Southern Appalachian region. Evolutionary geneticists traced the mutation back to British and Irish settlers who migrated to North America during colonial times, with its frequency increasing following a genetic bottleneck approximately 200 years ago. Senior study author Dr. Pasi A. Jänne highlighted that while current lung cancer screening strategies primarily focus on tobacco exposure, identifying strong genetic risk factors could enable targeted low-dose computed tomography screening for non-smoking carriers.
Gene Variants Might Elevate Lung Cancer Risk by Up to 60 Times in Non-Smokers
Supported by the National Institutes of Health, preclinical and clinical trials confirmed that this mutation exhibits a significant specific association with lung cancer, with no notable links to 17 other common cancers examined in the dataset. Oncologists emphasized that although tobacco use remains the primary cause of lung cancer, the increasing occurrence of lung cancer among non-smokers has become a major global health concern. Pharmaceutical companies, including AstraZeneca, are actively developing targeted therapies such as Tagrisso, a tyrosine kinase inhibitor, to treat EGFR-mutant lung cancers as tumors progress.
Co-senior author Dr. Alexander Gusev explained that this study illustrates how a single inherited point mutation can exert an exceptionally strong influence on disease risk. Medical professionals advise individuals with multiple affected family members, unexplained multifocal lung nodules, or ancestral ties to Southern Appalachia to seek genetic counseling. Researchers also emphasized that possessing the mutation does not guarantee a lung cancer diagnosis, as environmental factors and secondary genetic changes play roles in whether malignant transformation occurs over a lifetime.
Multicenter Study Examines Genetic Data from Over Three Million Participants
The collaborative research team intends to extend observational efforts via the ongoing INHERIT Study, focusing on additional inherited EGFR variants across diverse racial groups. The longitudinal research aims to identify environmental triggers and secondary genetic alterations that influence why some carriers develop tumors while others remain unaffected.
Findings concerning population genetics, risk assessments, and screening protocols remain available through peer-reviewed medical repositories and institutional release portals. Future updates, including biomarker data, will be presented at upcoming international oncology conferences to help shape screening guidelines moving forward.